Chemotherapy for advanced pancreatic cancer: it may no longer be ignored (Q33541099)

27 July 2017

1 reference

title

Chemotherapy for advanced pancreatic cancer: it may no longer be ignored (English)

1 reference

27 July 2017

1 reference

1 reference

S Cascinu

1

0 references

author name string

F Graziano

series ordinal

2

1 reference

PubMed ID

10076729

27 July 2017

G Catalano

series ordinal

3

1 reference

27 July 2017

1 January 1999

1 reference

27 July 2017

1 reference

27 July 2017

10

1 reference

27 July 2017

1

1 reference

27 July 2017

105-109

1 reference

27 July 2017

Cancer statistics, 1997.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Cancer in the European community and its member states

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

1 reference

7 January 2021

Should further studies of chemotherapy be carried out in pancreatic cancer?

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

No standard treatment is available for advanced pancreatic cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Chemotherapy for pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Chemotherapy for advanced pancreatic cancer. A comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM).

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. The Gastrointestinal Tumor Study Group

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Chemotherapy in pancreatic cancer: results of a controlled, prospective, randomised, multicentre trial.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. A Southwest oncology group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Chemotherapy prolongs survival in inoperable pancreatic carcinoma.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Activity of cisplatin in adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Phase II trial of 5-fluorouracil, leucovorin and cisplatin for treatment of advanced pancreatic adenocarcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Treatment of advanced pancreatic carcinoma with a combination of protracted infusional 5-fluorouracil and weekly carboplatin: a Mid-Atlantic Oncology Program Study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Phase II trial of CPT-11 in patients with advanced pancreatic cancer, an EORTC early clinical trials group study

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

A rationale for expanding the endpoints for clinical trials in advanced pancreatic carcinoma

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Phase II trial of gemcitabine (2,2'-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Phase II study of gemcitabine in patients with advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer.

1 reference

https://api.crossref.org/works/10.1023%2FA%3A1008205515591

7 January 2021

Identifiers

DOI

10.1023/A:1008205515591

1 reference

27 July 2017

1 reference

PubMed ID

10076729